Vaishali Pharma Limited (NSE:VAISHALI)
India · Delayed Price · Currency is INR 6.87
-0.36 (-4.98%)
Oct 23, 2026, 3:29 PM IST
Vaishali Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,079 | 1,088 | 990.26 | 862.8 | 696.63 | 758.21 |
Other Revenue | - | - | 0 | - | - | - |
| 1,079 | 1,088 | 990.26 | 862.8 | 696.63 | 758.21 | |
Revenue Growth | 3.08% | 9.84% | 14.77% | 23.85% | -8.12% | 41.00% |
Cost of Revenue | 945.32 | 952 | 857.12 | 744.37 | 547 | 635.17 |
Gross Profit | 133.85 | 135.73 | 133.14 | 118.43 | 149.63 | 123.04 |
Selling, General & Admin | 28.48 | 32.77 | 30.29 | 28.11 | 26.1 | 22.13 |
Other Operating Expenses | 63.06 | 40.76 | 46.52 | 28.03 | 29.75 | 32.06 |
Operating Expenses | 97.48 | 100.59 | 137.11 | 112.13 | 60.89 | 58.75 |
Operating Income | 36.37 | 35.14 | -3.97 | 6.3 | 88.74 | 64.29 |
Interest Expense | -18.26 | -19.63 | -15.83 | -17.37 | -22.56 | -24.89 |
Interest & Investment Income | - | 29.18 | 26.06 | 13.92 | 12.55 | 12.98 |
Earnings From Equity Investments | 1.9 | 1.33 | - | - | - | - |
Currency Exchange Gain (Loss) | - | 4.43 | 3.18 | 1.71 | 5.41 | 4.43 |
Other Non Operating Income (Expenses) | 35.73 | 4.75 | 2.82 | 4.7 | 4.33 | 0.47 |
EBT Excluding Unusual Items | 55.74 | 55.2 | 12.26 | 9.26 | 88.46 | 57.28 |
Pretax Income | 55.74 | 55.2 | 12.26 | 9.26 | 88.46 | 57.28 |
Income Tax Expense | 11.42 | 13.55 | 4.08 | 2.07 | 22.43 | 17.05 |
Net Income | 44.32 | 41.65 | 8.17 | 7.19 | 66.04 | 40.24 |
Net Income to Common | 44.32 | 41.65 | 8.17 | 7.19 | 66.04 | 40.24 |
Net Income Growth | 1014.61% | 409.52% | 13.70% | -89.11% | 64.12% | 284.58% |
Shares Outstanding (Basic) | 131 | 130 | 126 | 107 | 105 | 105 |
Shares Outstanding (Diluted) | 131 | 130 | 126 | 107 | 112 | 105 |
Shares Change | 2.23% | 3.15% | 17.99% | -4.07% | 5.95% | - |
EPS (Basic) | 0.34 | 0.32 | 0.06 | 0.07 | 0.63 | 0.38 |
EPS (Diluted) | 0.34 | 0.32 | 0.06 | 0.07 | 0.59 | 0.38 |
EPS Growth | 990.31% | 432.06% | -10.54% | -88.65% | 54.90% | 284.58% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -0.23 | -183.43 | 6.96 | 7.82 | 4.54 |
Free Cash Flow Per Share | - | -0.00 | -1.45 | 0.07 | 0.07 | 0.04 |
Gross Margin | 12.40% | 12.48% | 13.44% | 13.73% | 21.48% | 16.23% |
Operating Margin | 3.37% | 3.23% | -0.40% | 0.73% | 12.74% | 8.48% |
Profit Margin | 4.11% | 3.83% | 0.83% | 0.83% | 9.48% | 5.31% |
Free Cash Flow Margin | - | -0.02% | -18.52% | 0.81% | 1.12% | 0.60% |
EBITDA | 38.97 | 38.55 | -1.53 | 8.86 | 91.37 | 66.8 |
EBITDA Margin | 3.61% | 3.54% | -0.15% | 1.03% | 13.11% | 8.81% |
D&A For EBITDA | 2.59 | 3.41 | 2.45 | 2.57 | 2.63 | 2.51 |
EBIT | 36.37 | 35.14 | -3.97 | 6.3 | 88.74 | 64.29 |
EBIT Margin | 3.37% | 3.23% | -0.40% | 0.73% | 12.74% | 8.48% |
Effective Tax Rate | 20.49% | 24.55% | 33.32% | 22.37% | 25.35% | 29.76% |
Revenue as Reported | 1,115 | 1,126 | 1,022 | 883.13 | 718.92 | 776.09 |
Advertising Expenses | - | 3.63 | 4.48 | 4.86 | 5.29 | 0.86 |